11 clinical trials that will shape medicine in 2022

Despite the ongoing disruptions from COVID-19, 2021 saw some major results from clinical trials.

2022 looks to be a bumper year too, so Nature Medicine asks leaders in their field what they think will be the most important clinical trial results in the coming year.

Nature Medicine asks leading researchers to name their most anticipated clinical trial for 2022, from CRISPR and psilocybin to oncolytic viruses.

TreatmentCondition or diseaseSponsorPhase and size
Mosaic nanoparticle immunogen FluMos-v1InfluenzaNIAIDPhase 1; 35 participants
ASOsHuntington’s diseaseRoche / GenentechPhase 3; 791 participants
CRISPR-based gene therapy NTLA-2001Transthyretin amyloidosisRegeneron / Intellia TherapeuticsPhase 1; 38 participants
Miltefosine and paromomycinVisceral leishmaniasis (kala-azar)Drugs for Neglected Diseases InitiativePhase 3; 439 participants
PridopidineHuntington’s diseasePrilenia TherapeuticsPhase 2/3; up to 480 participants
AAV9 U7 snRNA gene therapyDuchenne muscular dystrophyNationwide Children’s Hospital / Audentes TherapeuticsPhase 1/2a; 3 participants
PsilocybinTreatment-resistant depressionCOMPASS PathwaysPhase 2a; 231 participants
Oncolytic vaccinia virus ASP9801Advanced or metastatic solid tumorsAstellasPhase 1; 105 participants
Monoclonal antibody nirsevimabRSVMedImmune / AstraZenecaPhase 3, 3000 participants
Monoclonal antibody pembrolizumabTriple negative breast cancerNational Cancer InstitutePhase 3; 1155 participants
VariousCOVID-19TOGETHER TrialAdaptive trial; various
NIAID, National Institute of Allergy and Infectious Diseases; AAV9, adeno-associated virus 9; snRNA, small nuclear RNA.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.